
Benjamin P. Blumel
Examiner (ID: 13928, Phone: (571)272-4960 , Office: P/1648 )
| Most Active Art Unit | 1648 |
| Art Unit(s) | 1648, 1671 |
| Total Applications | 1338 |
| Issued Applications | 802 |
| Pending Applications | 145 |
| Abandoned Applications | 411 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19784263
[patent_doc_number] => 20250057942
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-20
[patent_title] => NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS
[patent_app_type] => utility
[patent_app_number] => 18/941809
[patent_app_country] => US
[patent_app_date] => 2024-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10952
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18941809
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/941809 | Nucleic acid vaccine against the SARS-CoV-2 coronavirus | Nov 7, 2024 | Issued |
Array
(
[id] => 19999503
[patent_doc_number] => 20250137725
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-05-01
[patent_title] => RECOMBINANT VIRUS, COMPOSITION COMPRISING THE SAME, AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 18/804734
[patent_app_country] => US
[patent_app_date] => 2024-08-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11659
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18804734
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/804734 | Recombinant virus, composition comprising the same, and uses thereof | Aug 13, 2024 | Issued |
Array
(
[id] => 19629742
[patent_doc_number] => 20240408191
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-12-12
[patent_title] => NUCLEIC ACID VACCINES
[patent_app_type] => utility
[patent_app_number] => 18/801071
[patent_app_country] => US
[patent_app_date] => 2024-08-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 150178
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 57
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18801071
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/801071 | NUCLEIC ACID VACCINES | Aug 11, 2024 | Abandoned |
Array
(
[id] => 19784256
[patent_doc_number] => 20250057935
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-02-20
[patent_title] => ADENOVIRAL VECTOR SYSTEM FOR GENE DELIVERY
[patent_app_type] => utility
[patent_app_number] => 18/749120
[patent_app_country] => US
[patent_app_date] => 2024-06-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8662
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 49
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18749120
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/749120 | ADENOVIRAL VECTOR SYSTEM FOR GENE DELIVERY | Jun 19, 2024 | Pending |
Array
(
[id] => 19556463
[patent_doc_number] => 20240368255
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => Antibodies to Andes Hantavirus, and Methods for Using Same
[patent_app_type] => utility
[patent_app_number] => 18/747563
[patent_app_country] => US
[patent_app_date] => 2024-06-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9591
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18747563
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/747563 | Antibodies to Andes Hantavirus, and Methods for Using Same | Jun 18, 2024 | Pending |
Array
(
[id] => 19464480
[patent_doc_number] => 20240318149
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-26
[patent_title] => AAV Vectors
[patent_app_type] => utility
[patent_app_number] => 18/739986
[patent_app_country] => US
[patent_app_date] => 2024-06-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24440
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18739986
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/739986 | AAV Vectors | Jun 10, 2024 | Pending |
Array
(
[id] => 20372468
[patent_doc_number] => 12479891
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-25
[patent_title] => Methods of detection and removal of rhabdoviruses from cell lines
[patent_app_type] => utility
[patent_app_number] => 18/665250
[patent_app_country] => US
[patent_app_date] => 2024-05-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 5756
[patent_no_of_claims] => 27
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18665250
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/665250 | Methods of detection and removal of rhabdoviruses from cell lines | May 14, 2024 | Issued |
Array
(
[id] => 19585025
[patent_doc_number] => 20240382582
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-21
[patent_title] => Immunomodulatory proteins- or targeting proteins-expressing nanovesicles, methods of preparing the nanovesicle and use thereof
[patent_app_type] => utility
[patent_app_number] => 18/663339
[patent_app_country] => US
[patent_app_date] => 2024-05-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22701
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18663339
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/663339 | Immunomodulatory proteins- or targeting proteins-expressing nanovesicles, methods of preparing the nanovesicle and use thereof | May 13, 2024 | Pending |
Array
(
[id] => 19571887
[patent_doc_number] => 20240376179
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-14
[patent_title] => DNA ANTIBODY CONSTRUCTS FOR USE AGAINST MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS
[patent_app_type] => utility
[patent_app_number] => 18/656948
[patent_app_country] => US
[patent_app_date] => 2024-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18632
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18656948
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/656948 | DNA ANTIBODY CONSTRUCTS FOR USE AGAINST MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS | May 6, 2024 | Abandoned |
Array
(
[id] => 19570406
[patent_doc_number] => 20240374698
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-14
[patent_title] => COMPOSITIONS FOR USE IN TREATMENT OF ACNE
[patent_app_type] => utility
[patent_app_number] => 18/654557
[patent_app_country] => US
[patent_app_date] => 2024-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 88573
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 25
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18654557
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/654557 | Compositions for use in treatment of acne | May 2, 2024 | Issued |
Array
(
[id] => 19554946
[patent_doc_number] => 20240366738
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => MOLECULAR VACCINES FOR INFECTIOUS DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/643793
[patent_app_country] => US
[patent_app_date] => 2024-04-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 105075
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 60
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18643793
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/643793 | MOLECULAR VACCINES FOR INFECTIOUS DISEASE | Apr 22, 2024 | Pending |
Array
(
[id] => 19554953
[patent_doc_number] => 20240366745
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => TROPICAL DISEASE VACCINES
[patent_app_type] => utility
[patent_app_number] => 18/635203
[patent_app_country] => US
[patent_app_date] => 2024-04-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 91398
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18635203
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/635203 | TROPICAL DISEASE VACCINES | Apr 14, 2024 | Pending |
Array
(
[id] => 19554902
[patent_doc_number] => 20240366694
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-07
[patent_title] => PHAGE THERAPY OF E COLI INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 18/635105
[patent_app_country] => US
[patent_app_date] => 2024-04-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14137
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 74
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18635105
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/635105 | PHAGE THERAPY OF E COLI INFECTIONS | Apr 14, 2024 | Pending |
Array
(
[id] => 20787427
[patent_doc_number] => 12661322
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-06-23
[patent_title] => Multivalent nanoparticle-based vaccines
[patent_app_type] => utility
[patent_app_number] => 18/615895
[patent_app_country] => US
[patent_app_date] => 2024-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 15
[patent_no_of_words] => 24971
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 166
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18615895
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/615895 | Multivalent nanoparticle-based vaccines | Mar 24, 2024 | Issued |
Array
(
[id] => 19650067
[patent_doc_number] => 12171827
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-12-24
[patent_title] => Nucleic acid vaccine against the SARS-CoV-2 coronavirus
[patent_app_type] => utility
[patent_app_number] => 18/615472
[patent_app_country] => US
[patent_app_date] => 2024-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 12
[patent_no_of_words] => 10949
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 101
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18615472
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/615472 | Nucleic acid vaccine against the SARS-CoV-2 coronavirus | Mar 24, 2024 | Issued |
Array
(
[id] => 19403633
[patent_doc_number] => 20240287144
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-08-29
[patent_title] => SELF-ASSEMBLING INSECT FERRITIN NANOPARTICLES
[patent_app_type] => utility
[patent_app_number] => 18/615011
[patent_app_country] => US
[patent_app_date] => 2024-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35147
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18615011
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/615011 | Self-assembling insect ferritin nanoparticles | Mar 24, 2024 | Issued |
Array
(
[id] => 20083741
[patent_doc_number] => 20250213677
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2025-07-03
[patent_title] => DRUG-DELIVERY COMPOSITION INCLUDING PLANT-DERIVED NANOVESICLES AS ACTIVE INGREDIENTS
[patent_app_type] => utility
[patent_app_number] => 18/611577
[patent_app_country] => US
[patent_app_date] => 2024-03-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 0
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18611577
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/611577 | DRUG-DELIVERY COMPOSITION INCLUDING PLANT-DERIVED NANOVESICLES AS ACTIVE INGREDIENTS | Mar 19, 2024 | Pending |
Array
(
[id] => 19433020
[patent_doc_number] => 20240301518
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-12
[patent_title] => MICROBIAL BIOMARKERS IN TRANSPLANTATION AND RELATED METHODS
[patent_app_type] => utility
[patent_app_number] => 18/610208
[patent_app_country] => US
[patent_app_date] => 2024-03-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44530
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18610208
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/610208 | MICROBIAL BIOMARKERS IN TRANSPLANTATION AND RELATED METHODS | Mar 18, 2024 | Pending |
Array
(
[id] => 19280028
[patent_doc_number] => 20240216501
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-04
[patent_title] => NEOANTIGEN ADJUVANT AND MAINTENANCE THERAPY
[patent_app_type] => utility
[patent_app_number] => 18/607027
[patent_app_country] => US
[patent_app_date] => 2024-03-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52193
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -46
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18607027
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/607027 | NEOANTIGEN ADJUVANT AND MAINTENANCE THERAPY | Mar 14, 2024 | Pending |
Array
(
[id] => 19281906
[patent_doc_number] => 20240218380
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-07-04
[patent_title] => OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS
[patent_app_type] => utility
[patent_app_number] => 18/582939
[patent_app_country] => US
[patent_app_date] => 2024-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29697
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 118
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18582939
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/582939 | OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS | Feb 20, 2024 | Pending |